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Protocol for a systematic review of time to
antibiotics (TTA) in patients with fever and
neutropenia during chemotherapy for
cancer (FN) and interventions aiming to
reduce TTA
Christa Koenig1,2* , Jess Morgan2, Roland A. Ammann1, Lillian Sung3 and Bob Phillips2,4
Abstract
Background: Fever and neutropenia (FN) is a common complication of chemotherapy for cancer. Prompt empiric
broad-spectrum antibiotic therapy in FN is typically considered standard of care, but the definition of prompt is not
clear. We seek to systematically review the available data on the association between time to antibiotics (TTA)
administration and clinical outcomes in patients with FN being treated with chemotherapy. There have been
several efforts to reduce TTA in patients with FN, by implementing specific interventions, presuming there will be a
beneficial effect on patient-important outcomes. This systematic review will also collect data on such interventions
and their effect to reduce TTA and potentially change clinical outcomes.
Methods/design: The search will cover MEDLINE, MEDLINE In-Process & Other Non-Indexed Citations, EMBASE,
CINAHL, CDSR, CENTRAL, and LILACS. A full-search strategy is provided. Lists of studies identified by references cited
and forward citation searching of included articles will also be reviewed. Studies will be screened, and data
extracted by one researcher and independently checked by a second. Confounding biases and quality of studies
will be assessed with the risk of bias in non-randomised studies-of interventions (ROBINS-I) tool.
Data will be presented in narrative and tabular forms; in addition, if appropriate data is available, random effects
meta-analysis will be used to examine TTA.
A detailed analysis plan, including an assessment of heterogeneity and publication bias, is provided.
Discussion: This study aims to evaluate the association between TTA and patient-important clinical outcomes.
Additionally, it will identify, critically appraise, and synthesise information on performed interventions and its effect
to reduce TTA as a way of gaining insight into the potential use of these approaches. This will provide better
knowledge for an adjusted treatment approach of FN.
Systematic review registration: PROSPERO [CRD42018092948]
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Background
Fever in chemotherapy-induced neutropenia (FN), if due
to infection, is the most frequent potentially lethal com-
plication of chemotherapy for cancer [1]. When absolute
neutrophil count (ANC) drops below 0.5 × 109/l, the risk
of life-threatening bacterial infection increases [2]. Time
to antibiotics (TTA) usually refers to the amount of time
passed from arrival at the hospital to start of intravenous
antibiotic administration [3–5]. Different definitions are
sometimes used, for example, time from the first detec-
tion of fever [6] (Fig. 1).
Delays in presenting to medical care with fever may be
one of the main reasons for poor outcome in FN; never-
theless, current European and American guidelines for
treatment of FN in adult patients with cancer recom-
mend administration of empiric broad-spectrum antibi-
otics within 1 h from the admission of a patient with FN
[7, 8]. International FN guidelines for paediatric patients,
developed by an international panel of experts, do not
specify a target TTA [9]; the current German paediatric
guidelines for treatment of FN recommend administra-
tion of antibiotics within 60min without giving specific
evidence [10]. Some organisations have defined TTA <
60min as a measure of quality of care [5], but no sys-
tematic review has investigated the association of TTA
and outcome in cancer patients.
Recommendations are based mainly on studies involv-
ing immunocompetent subjects with severe sepsis. In
adult patients with severe sepsis [11] and meningitis [12,
13], delay in antibiotic administration is associated with
a decrease in survival. After the onset of shock, there
has been reported an increase in mortality of 7.6% for
each hour delay [14]. Although strong and pathophysio-
logically sound, this association cannot directly be ex-
trapolated to patients undergoing chemotherapy for
cancer.
Damage to the gastrointestinal mucosa caused by anti-
cancer agents provides a portal of entry for pathogenic
bacteria, and the frequent need for indwelling central
venous catheters allows for colonisation by an entry of
Gram-positive skin flora [6]. These and other factors
alongside chemotherapy-induced immunodeficiency pre-
dispose patients with cancer to bacteremia. Antibiotic
treatment is initiated relatively early in all patients, un-
like immunocompetent adults and, in contrast to the
significantly ill patients that were examined in sepsis
studies, fever is often the only clinical sign for infection.
Overlapping parameters due to the impact of chemo-
therapy, e.g. therapy-induced thrombopenia, anaemia, or
liver dysfunction, complicate detection and potentially
outcomes of severe infections in cancer patients differ-
ently and may mean direct comparisons are inaccurate.
In summary and particularly in paediatric oncology
there is a lack of evidence for the impact of TTA on out-
come in FN.
A systematic review and meta-analysis will help to set-
tle the controversies of conflicting studies, as well as to
identify gaps in the current research and areas for fur-
ther study.
Evidence identifying the importance of TTA is needed
for an adjusted treatment approach and optimal TTA. If
shown to be of low value, focus on other aspects of the
treatment pathway than time, e.g. a rigorous diagnostic
work, could improve quality of treatment.
Aims, objectives, and overview of approach
This systematic review aims to evaluate the association
between TTA and patient-important clinical outcomes
and to explore the effect of important covariates on
modifying outcomes in patients with FN during chemo-
therapy for cancer. We aim to define what TTA can be
considered safe with regard to outcome. Additionally,
the review will provide more detailed information about
how important covariates of TTA are correlated with
the outcome of FN episodes.
Drawing on pathophysiological models and previous
work [15], we hypothesise shorter TTA will lead to re-
duced severe clinical illness, with less need for organ
support, critical care, and reduced mortality rates. It has
to be evaluated whether this is an accurate hypothesis
for well-appearing patients or only for patients present-
ing already critically ill. The prompt treatment of
Fig. 1 Scheme: time to antibiotics in patients with fever in neutropenia
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infection may also lead to a reduced probability of dis-
semination of infection, and so shorter duration of fever,
fewer relapses of infections or recurrences of fever, and
shorter periods of hospitalisation for FN treatment
(Fig. 2). We do not expect that TTA should be associ-
ated with the chance of identifying bacteraemia in initial
investigations, as a bloodstream infection will either be
present or not.
Several groups have attempted to reduce TTA in pa-
tients with FN during chemotherapy for cancer by
implementing specific intervention in emergency depart-
ments (ED) and oncology wards. This systematic review
will also identify, critically appraise, and synthesise infor-
mation on interventions performed and their effect on
TTA reduction in order to gain insight into the potential
use of these approaches. If data exists, we will evaluate
the impact of interventions that reduce TTA on import-
ant outcomes.
The close relationship between these two objectives
justifies their combination. They are likely to be discov-
ered during the same electronic search strategies and
some studies will address both questions, saving
duplication.
Methods/design
This protocol specifies the conduct and reporting of a sys-
tematic review and meta-analysis in compliance with the
guideline Preferred Reporting Items for Systematic Re-
views and Meta-analyses (PRISMA) [16]. The systematic
review will be undertaken following guidelines from the
Cochrane Collaboration [17] and the Centre for Reviews
and Dissemination (CRD) of the University of York [18].
The protocol for the review is registered in the PROS-
PERO Database [CRD42018092948]. The work for this re-
view started in May 2018, and its publication is planned
for summer 2019.
As this study is a systematic review of primary studies,
no ethical approval is required.
Search and retrieval strategy
Electronic sources will be searched for relevant studies
including MEDLINE, MEDLINE In-Process & Other
Non-Indexed Citations , EMBASE, CINAHL, CDSR,
CENTRAL, and LILACS.
Lists of studies identified by references cited and for-
ward citation searching (using ‘cited by’ in Google
Scholar) of included articles will also be reviewed. The
search strategy will include the Medical Subject Heading
terms and text words to identify fever and neutropenia
and the intervention of antibiotics. Antibiotics will also
be searched by groups and names of antibiotic drugs
(e.g. penicillins, beta-lactams, quinolones).
As a decision of balance between sensitivity and feasi-
bility, EMBASE searches ‘time’ will be added as a re-
quired search factor to narrow the results. As most of
the studies in neutropenic patients are cancer patients,
we will not include a cancer filter in our search strategy.
Fig. 2 Scheme: pathophysiological model for different times to antibiotics
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The full-search strategies are included in Additional file 1:
Appendix 1.
The study selection process will be piloted by applying
the search strategy to a sample of five papers in order to
check that the correct papers would be identified.
Published and unpublished studies will be sought, and
no language restrictions applied. The latter is important
because we suspect that there may be a number of stud-
ies that have been performed in Spain, Portugal, and
South America as these areas have active research in
paediatric oncology FN research. Non-English language
studies will be translated if this is possible within 3
months of running the searches; if unable to translate,
this will be noted. This time limit will ensure that the re-
sults of this review are available to inform further as-
pects of an overarching PhD project. Where two
publications reporting the same study exist, the one with
the outcomes matching the review outcomes will be
selected.
Authors of relevant studies and prominent clinicians
within the field will be contacted as time allows seeking
further studies, as this is likely to be a poorly indexed
area of biomedical research (see Additional file 1, Ap-
pendix 2). If authors or the contacted clinicians provide
unpublished or additive data beneficial for answering
our review question, this data will be included.
The Society of Infectious Diseases of America pub-
lished the first practice guidelines for the use of anti-
microbial agents in neutropenic patients with fever in
1997 [19]. Since then, the standard management for all
patients developing a fever while neutropenic has been
empiric antibiotic treatment. Before this, practice was
less consistent; therefore, studies from 1997 onwards will
be included in this review.
Screening for eligibility
The decision on the inclusion of a study will be made
initially by screening the titles and abstracts of retrieved
papers against the inclusion criteria by one reviewer
(CK) to identify potentially relevant papers. After read-
ing the full text of all potentially eligible studies, the final
decision on whether to include them in the review or
not will be made. A second reviewer will independently
screen a sample of 50% of the retrieved papers. The
kappa statistic for agreement will be calculated, and if
this shows significant disagreement (κ < 0.4), all titles
and abstracts will be screened by the second reviewer. In
case of disagreement for inclusion, a consensus decision
will be reached after discussion and if necessary by re-
course to an independent adjudicator.
Inclusion and exclusion criteria
Studies will be included if they meet the following
criteria:
Study designs
It is not possible to do TTA randomisation, and it is not
anticipated that many controlled studies will be available
for both of our review questions. Therefore, observa-
tional studies, such as cohort studies and case-control
studies are eligible for inclusion as well. In practice, the
partial implementation of a time-reducing method may
not be possible in one institution. So quasi-experimental
studies as before-and-after studies and interrupted time
series studies and studies with quality improvement
methodology will be included. Studies examining the ef-
fect of attempting to reduce TTA are only included if
they provide data from a comparison group.
Studies included may be retro- or prospective. Case re-
ports are excluded from the review, owing to the high
potential for bias in this study design.
Published studies, conference abstracts, and interim
results will be included, but excluded if they provide in-
sufficient data.
Population
Human participants who are receiving treatment for
cancer (including leukaemias), presenting with FN will
be included.
Combining results from adult and paediatric patients
will enhance the number of patients and improve the
validity of the analysis. Even when adult data may not be
directly transferable to paediatric patients due to higher
incidence of comorbidities, a different spectrum of can-
cer diseases and often less intense chemotherapy, draw-
ing the reports together and synthesising their results
will add to our understanding of TTA. It may allow
broader analysis of confounding factors and increase the
chance of discovering important covariates.
Interventions and comparators
Treating FN with any antibiotics will be the only re-
quired treatment criteria. For studies examining the as-
sociation of TTA with outcomes, no additional
intervention or comparator will be required as long vs.
short TTA will be the comparator. If patients are in-
cluded who have not been given antibiotics for the index
episode, these will be noted but their data cannot be in-
cluded in an analysis of TTA. It is likely that there is a
difference within the association of TTA and clinical
outcomes in TTA starting at detection of fever, com-
pared to TTA starting at arrival at the hospital. TTA will
be collected regardless of the used definition but the dif-
ferences will be considered in discussion.
We are aware there are a variety of treatment regimes
including IV therapy, oral therapy, and outpatient ther-
apy. This creates a challenge as TTA may be influenced
by the way of administration of antibiotics, e.g. oral
treatment can be started faster, given that there is no
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need for intravenous access. Exclusion of oral treatment
could overestimate the effect of longer TTA on out-
come, because oral treatment, and for this reason, po-
tentially shorter TTA, is more often given to low-risk
patients. In contrary, it could underestimate the effect of
TTA if IV antibiotics are more effective and therefore re-
sult in less adverse outcomes. Since we want to have a
look at TTA as an independent variable regarding the
outcome, it is justified to include all methods of admin-
istration in one review.
There are numerous different antibiotic regimes, in
both adult and paediatric protocols [7–10]. The coverage
of these antibiotics is certainly less varied than the spe-
cific antibiotics used: thus, differences between regimes
are more likely to be related to the route of administra-
tion, including absorption and dosing, than the specific
antibiotic used.
There will be no eligibility restriction concerning the
definitions of fever and neutropenia but as they could
influence TTA and outcomes they will be extracted and
evaluated when comparing and pooling results.
Studies investigating an intervention or combination
of interventions with the aim to reduce TTA in patients
with cancer and FN will be included. Interventions can
be implemented in inpatient or outpatient settings, per-
formed by any person included in the FN management
(e.g. nurses/physicians/patients/parents), and patient in-
formation/education would also be an included interven-
tion. Interventions may be grouped during analysis (e.g.
process changes, educational change) if considered
appropriate.
There must be a comparison group cared for in the
same way in the setting and with the same treatment
regimens, except for the intervention studied. The com-
parison group can be of the same cohort and may be ob-
served simultaneously or successively.
Outcomes
There is marked variability in FN outcomes that are col-
lected and reported [20]. An international collaborative
group developed core outcomes [21] for febrile neutro-
penia research; the outcomes that should be collected
within studies in FN are death, serious medical compli-
cation (admission to intensive care unit (ICU), severe
sepsis, including septic shock), and potentially other out-
comes like bacteremia, clinically or microbiologically
documented infection, all-cause 30-day mortality, relapse
of primary infection. These comprise the key outcomes
which are patient, clinician, and research important and
an effort will be made to examine these as key compos-
ite outcomes.
As this core outcome set is relatively new, the pub-
lished outcomes will likely not be reported in full, and
so the inclusion of studies will not be restricted to those
who report these in detail. We expect studies which are
likely to be included to have generally reported compos-
ite outcomes, possibly using different elements, rather
than individual medical complications. Former multi-
national guidelines have recommended that the primary
outcome of studies into FN should be such a composite
measure [22]. The analysis in the review will necessarily
be based on the definitions of outcomes within the ori-
ginal studies; these definitions will be collected alongside
the outcome data.
Primary outcomes
There will be three primary outcomes in this review:
safety and treatment adequacy (for all studies) and time
to antibiotics (for those studies evaluating interventions).
Safety
Exploration of safety will consider death and serious
medical complication (admission to ICU, severe sepsis,
including septic shock) as a primary outcome. Know-
ledge about the safety of TTA is essential to be able to
consider any adjustment for the treatment approach for
FN.
Treatment adequacy
Delay in antibiotic administration may lead to dissemin-
ation and protraction course of an infection. Clinical
signs of a protracted infection may be a relapse of pri-
mary infection and persistence of fever for more than
5 days after the start of treatment or recurrence of fever
without a new infection. We will use treatment adequacy
as a composite outcome to see whether a shorter TTA
produces better treatment efficiency. Certainly, treat-
ment adequacy is influenced by other variables as well,
which will be explored in the secondary outcomes.
To be included, a study has to have recorded and pro-
vided data for one or more of the elements of the pri-
mary outcomes. We acknowledge that each study is
unlikely to select an outcome that completely fits the
definition given above. Therefore, the composite out-
come that each individual study selects will be recorded
within the data collection stage of this systematic review,
and it may be only specific outcomes (for example,
death, or admission to ICU) are reported in the different
studies.
For studies which examine an intervention to assess
its effects, there will be a further primary outcome
assessed:
Time to antibiotics
For the analysis of the effect of specific interventions,
the absolute reduction of TTA will be the primary out-
come (process measure).
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Secondary outcomes
As secondary outcomes, the individual components of
safety and treatment adequacy will be analysed separ-
ately. For the analysis of the effect of specific interven-
tions, the described primary and secondary outcomes of
FN will be analysed as secondary outcomes.
Secondary outcomes will also include outcomes which
may allow us to understand confounding. These are
microbiologically defined infection, new infections, and
modification of antibiotics and measurements of TTA
other than absolute. We expect that these outcomes are
not affected due to faster administration of antibiotics,
but they may be influenced by the same covariates that
influence treatment adequacy. As such, they will be used
as negative controls for the association of TTA on safety
and adequate treatment.
Additionally, days of fever and days of hospitalisation
will be assessed. These may be influenced by the ad-
equacy of initial antibiotic treatment and will not be
regarded as negative controls for the association of TTA
on safety and adequate treatment.
Data extraction and assessment of risk of bias
Data will be extracted by one researcher (CK) using a
standardised data extraction form (see Additional file 1,
Appendix 3) and independently checked by a second
(RAA). Intervention characteristics will be collected ac-
cording to the Cochrane Effective Practice and Organ-
isation of Care Review Group (EPOC) data collection
checklist [23]. If the data to be extracted is unclear or
not specific enough, authors will be contacted for fur-
ther information. If there is no response, a further at-
tempt to make contact will be made a fortnight later. If
there is no response after a further 4 weeks, the data will
be presumed unavailable. No data imputation is planned
for missing data, and thus, studies with missing data will
not be included in specific syntheses.
We expect several confounding factors. These may be
patient-related factors as age, comorbidities, and initial
illness severity. More rapid treatment of patients at
higher risk will generate a triage bias. In contrary, the
way of administration of antibiotics can create an inverse
triage bias, as oral treatment for low-risk patients can be
started faster. Structural factors as setting at FN diagno-
sis, localisation, and time of presentation may be import-
ant confounders as well, influencing TTA and outcome.
The risk of bias in non-randomised studies–of interven-
tions (ROBINS-I) tool [24] will help to assess biases,
quality of the studies, and plan analysis appropriately.
Furthermore, a publication bias is expected, as suc-
cessful interventions are more likely to be published
than unsuccessful ones. Where possible, funnel plots of
the study outcomes will be used to explore this. Expect-
ing substantial in between-study heterogeneity, Rücker’s
method [25] will be used as asymmetry test, if more than
10 studies are included in the meta-analysis [26].
Methods of analysing/synthesis
Key study characteristics, study quality and the interven-
tions aiming to reduce TTA will be described and sum-
marised in narrative and tabular forms.
If it is considered appropriate (based on clinical and
statistical homogeneity and the necessary data being
available), meta-analysis will be undertaken in order to
examine whether TTA is associated with safety, treat-
ment adequacy, and how these are influenced by poten-
tial confounders. It is likely that any pooled analysis will
only be possible with a subset of studies.
TTA will be categorised as within 1 h or more than 1
h, because current guidelines recommend administration
within 1 h after arrival at the hospital [7, 8, 10]. Other
definitions and analysis will be used, such as hourly in-
crements or continuous TTA, within a sensitivity ana-
lysis. Results of studies with TTA starting at detection of
fever will not be pooled with studies with TTA starting
at arrival at the hospital. In the narrative analysis, TTA
definition will be described and examined as a possible
source of variation.
Odds ratios and 95% confidence intervals (CI) will be
calculated or extracted for binary outcomes, standard
mean difference (SMD), and 95% CI for continuous out-
comes. The chosen effect measures will then be com-
bined using a random effects model, given the
anticipated clinical heterogeneity and reported with 95%
confidence interval of the estimate and 95% prediction
interval of the potential results found in future studies.
All calculations will be done using the ‘R’ statistical en-
vironment. Forest plots will be presented for each out-
come. For studies that provide them, data which are
adjusted for covariates (e.g. clinical features suggestive of
poor clinical outcome), will be pooled separately from
unadjusted estimates.
Narrative synthesis will be undertaken to examine the
association of TTA and outcome considering the risk of
bias and potential mechanisms which lead to heteroge-
neous outcomes where data pooling is not appropriate.
Heterogeneity
Heterogeneity will be explored through consideration of
study populations, study quality, and outcomes chosen.
If possible, it will be quantified by using I2 (< 40% repre-
senting unimportant, 30 to 60% moderate, 50 to 90%
substantial, and 75 to 100% considerable heterogeneity
[17]), assessed with the Cochran’s Q test (chi-squared
test, p value < 0.05 considered significant) and visualised
by forest plots [17].
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Subgroups
Subgroup analyses
A priori specified stratified analysis (if sufficient studies)
is planned by:
Adult vs. paediatric
Due to differences in the disease spectrum, applied
chemotherapy, incidence of comorbidities, and constitu-
tional differences, results in adults cannot be directly
transferred to children. Subgroup analysis will allow rea-
soning about differences in adults and children and
whether it makes sense to use guidelines for adults in
paediatric patients and vice versa. It will help to define
reasonable recommendations for each group of patients.
Age less than 18 years at FN diagnosis will be the defin-
ition for a paediatric patient or as defined by authors of
the original studies.
High risk vs. low risk
Patients with FN are a heterogeneous population, with
only a small proportion developing a serious medical
complication. Studies who distinguished patients
through initial risk stratification will allow separate ana-
lysis according to different risk groups. This will help to
identify and minimise bias due to administration route,
owing to the simpler and therefore more rapid treatment
with oral antibiotics in low-risk patients and triage bias
because severely ill patients are more likely to receive
rapid treatment than patients in a good general condi-
tion. We will use the study’s definition to define the risk
groups.
Severe neutropenia vs. non-severe neutropenia
An absolute neutrophil count (ANC) of < 0.5 × 109/l is
considered to be severe neutropenia [8] and most of the
time the level used as definition for FN. The ANC level
has been identified as factor for risk stratification in FN
[9] and is used to define duration of therapy [7]. In this
review, different definitions for neutropenia will be cap-
tured and some studies may include patients with
non-severe neutropenia (ANC > 0.5 × 109/l). Sub-group
analysis will enable to distinguish between patients with
non-severe neutropenia where antibiotics are not needed
and therefore TTA does not make a difference and those
with severe neutropenia, where more rapid treatment
may have an influence on clinical outcome.
Comorbidities vs. no comorbidities in adult patients
Adult patients are more likely to have comorbidities. A
separate analysis of patients without comorbidities is a
more appropriate approach to compare adult data with
paediatric patients. Relevant comorbidities must be
present before admission for FN and may be any pres-
ence of a major abnormality in regard to organ
dysfunction (for example, renal failure), comorbid condi-
tions (for example, previous stroke), as demonstrated
potentially through abnormal vital signs, clinical signs or
symptoms, and laboratory or imaging data.
They will be collected and patients grouped into no
comorbidities and with comorbidities defined as having
any or multiple of the listed comorbidities.
Antibiotic prophylaxis vs. no prophylaxis
Administration of antibiotic agents to patients after
chemotherapy, be it with or without neutropenia, with-
out any suggestive signs or symptoms, reduces the inci-
dence of infection and in some studies the
infection-related mortality [27]. Positive microbiological
detection rates by standard blood cultures vary depend-
ing on whether or not patients have received prophylac-
tic antibiotics [7].
Centres that do not use the commonly given Fluoro-
quinolone prophylaxis report a predominance of
Gram-negative bacteria [7] and usually Gram-positive
infection result in a lower mortality than Gram-negative
bacteria. A subgroup analysis will allow a more accurate
conclusion on the effect of TTA on outcome and
whether its impact is the same for patients who receive
prophylaxis versus patients who do not.
Inpatients vs. outpatient FN
It is likely that patients with inpatient episodes of FN re-
ceive antibiotics faster than outpatients due to accessible
IV line, no need for transport to the ED and no waiting
time due to capacity constraints in EDs. Conversely, the
reason for being an in-patient, such as the intensity of
chemotherapy and general clinical condition may be im-
portant covariates for outcome. As these elements may
differ significantly between out- and inpatients a sub-
group analysis is sensible.
Localisation of presentation (emergency department vs.
oncology unit)
One study has shown presentation to the ED having a
longer TTA than when patients are admitted directly to
the oncology unit, and presentation to the ED increases
the risk of poor outcome [4]. This may be attributed due
to high patient volumes in the ED setting, experience of
personnel or different hours, and reasons for presenta-
tion (e.g. delayed detection of fever at night). Examining
this across multiple studies will test this hypothesis
further.
Admission time (night vs. day and weekend vs. rest of the
week)
Several studies had shown that out-of-hours admission
to hospital may increase patient mortality or morbidity
[28, 29]. There are differences in emergency processes
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when we compare out-of-hour to working hours.
Waiting-time and conduction of laboratory results may
be longer on weekends and evenings and consultation
with an oncologist may take more time.
Discrete analysis of admission times will show whether
there are differences in TTA and can help to identify
sources of delays and reasons for unsuccessful interven-
tion approaches. This will be interesting and helpful
when examining which interventions are effective and
sensible for reduction of TTA.
Low/middle-income country vs. high-income country
We expect different barriers to providing rapid access to
antibiotics and potentially different covariates influen-
cing TTA among low/middle- and high-income coun-
tries. A study in a lower middle-income country has
identified longer travel times, illiteracy, and poverty to
be associated with delays in treatment of fever in paedi-
atric leukaemia [15]. These variables may matter less in
high-income countries. Subgroup analysis will allow us
to explore differences and will be useful for future the
planning of effective TTA reducing interventions in dif-
ferent developed countries.
Methods of dissemination
The results of this review will be written for publication
in a scholarly journal following the PRISMA reporting
guidelines as closely as possible [16]. Areas of uncer-
tainty and suggestions for further research will be out-
lined within the final report.
Discussion
To make recommendations for targeted TTA, it is im-
portant to know whether the chosen timespan is safe
and whether earlier antibiotic treatment can reduce
complications of infections. In an effort to examine these
key outcomes, we defined primary outcomes taking into
account the views of patients, clinicians, and researchers
as exemplified by the previously published core outcome
data set [21]. The inclusion of studies will not be re-
stricted to studies that report these in detail, as not all
will report enough data for the defined primary out-
comes. The chosen secondary outcomes will allow us to
undertake a useful analysis even if a lack of reported pri-
mary outcomes exists.
We expect studies that are likely to be included to
have generally reported composite outcomes, possibly
using different elements, rather than individual medical
complications. The analysis in the review will necessarily
be based on the definitions of outcomes within the ori-
ginal studies; these definitions will be collected alongside
the outcome data. In order to undertake the most com-
prehensive and accurate analysis possible, we will ask
authors for more specific and fragmented data of used
composite outcomes.
Specific limitations in the currently available data about
TTA are expected, for example, the analysis of TTA in dif-
ferent clinically defined risk groups, e.g. high risk/low risk
of adverse outcome of FN [9, 30]. Further, covariates that
influence TTA (e.g. triage bias, waiting time for laboratory
results, organisation streamlining) may be reported vari-
ably, and a comprehensive assessment would be valuable
for the planning of future studies.
We will collect outcomes we do not expect to be af-
fected by faster administration of antibiotics. They will
be used as negative controls for the association of TTA
on safety and treatment adequacy. Additionally, we de-
fined a list of preferable subgroup analysis to embrace
the complexity of important covariates.
In practice, TTA is often longer than the 60min sug-
gested in guidelines [3, 31]. Assuming that a shorter TTA
leads to clinical benefits, several groups have tried to iden-
tify and reduce sources of delay by implementing inter-
ventions in EDs or hospital wards [3, 31–33]. Such
interventions may include education of patients, imple-
mentation of staff consensus guidelines, high triage level
for all patients with FN, and rapid rooming in of all pa-
tients with FN, alone or in combination. A systematic re-
view collecting studies evaluating such interventions will
help to identify reasonable interventions amenable to
translation into clinical care and avoid repetition of unsuc-
cessful approaches. It will also outline whether there is the
need for further development of such interventions.
Besides the exclusion of case reports, there will be
no restriction on study design. Although outcomes
may change over time for reasons unrelated to the
implemented intervention, we will include
before-and-after studies even in the absence of inter-
rupted time series analysis, what should be the pri-
mary analytic approach [34]. Before-and-after studies
are confounded by time and may be triggered by a
series of prior, unreported events, leaning to regres-
sion to the mean. Their effect on TTA has to be ap-
praised carefully, but they will let us identify the
range of interventions proposed and may offer pos-
sible solutions for individual local problems. As one
goal is to describe and collect intervention strategies
to disseminate knowledge or facilitate practice change
to reduce TTA, exclusion of those would miss im-
portant information.
Collection of intervention characteristics according to
the EPOC data collection checklist will allow us to clas-
sify interventions and make analysis more structured.
In summary, the findings from the review will be used
to explore the implications of different TTA and
TTA-reducing interventions, with the aim of informing
future research and practice.
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This will provide better knowledge for an adjusted
treatment approach of FN in patients during chemother-
apy for cancer.
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